Mesenchymal stem cells: A promising way in therapies of graft-versus-host disease

46Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

Abstract

It is well acknowledged that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for numerous malignant blood diseases, which has also been applied to autoimmune diseases for more than a decade. Whereas graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a common serious complication, seriously affecting the efficacy of transplantation. Mesenchymal stem cells (MSCs) derived from a wealth of sources can easily isolate and expand with low immunogenicity. MSCs also have paracrine and immune regulatory functions, leading to a broad application prospect in treatment and tissue engineering. This review focuses on immunoregulatory function of MSCs, factors affecting mesenchymal stem cells to exert immunosuppressive effects, clinical application of MSCs in GVHD and researches on MSC-derived extracellular vesicles (EVs). The latest research progress on MSC in related fields is reviewed as well. The relevant literature from PubMed databases is reviewed in this article.

Cite

CITATION STYLE

APA

Zhou, X., Jin, N., Wang, F., & Chen, B. (2020, April 7). Mesenchymal stem cells: A promising way in therapies of graft-versus-host disease. Cancer Cell International. BioMed Central Ltd. https://doi.org/10.1186/s12935-020-01193-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free